VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Fowler on Different Responses to Therapy for Follicular Lymphoma

Nathan Fowler, MD
Published: Wednesday, Mar 29, 2017



Nathan Fowler, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the differences in response to the same therapy for patients with follicular lymphoma.

It has been well known that patients with follicular lymphoma behave very differently with the same therapy, explains Fowler. Some patients who are receiving the same therapy can have a median survival of 3 to 5 years, whereas others can have a median survival of 14 years. The field has been moving to identify those patients with different types of biological and clinical factors.

Several years ago, the FLIPI scoring system was developed, which looks at 5 clinical factors in patients before they receive treatment. The FLIPI score is able to successfully predict the patients who will have positive or negative outcomes, states Fowler.
 


Nathan Fowler, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the differences in response to the same therapy for patients with follicular lymphoma.

It has been well known that patients with follicular lymphoma behave very differently with the same therapy, explains Fowler. Some patients who are receiving the same therapy can have a median survival of 3 to 5 years, whereas others can have a median survival of 14 years. The field has been moving to identify those patients with different types of biological and clinical factors.

Several years ago, the FLIPI scoring system was developed, which looks at 5 clinical factors in patients before they receive treatment. The FLIPI score is able to successfully predict the patients who will have positive or negative outcomes, states Fowler.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x